RYBREVANT®▼ (Amivantamab) Plus Lazertinib Shows Longer Progression-Free Survival Versus Osimertinib In The First-Line ...
(MENAFN- GlobeNewsWire - Nasdaq) Investigational chemotherapy-free regimen of amivantamab plus lazertinib addresses a significant unmet need as most patients with EGFR-mutated NSCLC have high-risk disease1 Landmark Phase 3 MARIPOSA data featured in an oral …